• 1
    Mazur EM, Rosmarin AG, Sohl PA, Newton JL, Narendran A. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood 1992; 79: 19317.
  • 2
    Solberg LA Jr, Tefferi A, Oles KJ, Tarach JS, Petitt RM, Forstrom LA, Silverstein MN. The effects of anagrelide on human megakaryocytopoiesis. Br J Haematol 1997; 99: 17480.
  • 3
    Thiele J, Kvasnicka HM, Schmitt-Graeff A. Effects of anagrelide on megakaryopoiesis and platelet production. Semin Thromb Hemost 2006; 32: 35261.
  • 4
    Hong Y, Erusalimsky JD. Comparison of the pharmacological mechanisms involved in the platelet lowering actions of anagrelide and hydroxyurea: a review. Platelets 2002; 13: 3816.
  • 5
    Wang G, Franklin R, Hong Y, Erusalimsky JD. Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures. Br J Pharmacol 2005; 146: 32432.
  • 6
    Hong Y, Wang G, Del Arroyo AG, Hernandez J, Skene C, Erusalimsky JD. Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage. Leukemia 2006; 20: 111722.
  • 7
    Kaushansky K. Thrombopoietin. N Engl J Med 1998; 339: 74654.
  • 8
    Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005; 115: 333947.
  • 9
    Kaushansky K. Thrombopoietin: a tool for understanding thrombopoiesis. J Thromb Haemost 2003; 1: 158792.
  • 10
    Severin S, Ghevaert C, Mazharian A. The mitogen-activated protein kinase signalling pathways: role in megakaryocyte differentiation. J Thromb Haemost 2010; 8: 1726.
  • 11
    Shivdasani RA. Molecular and transcriptional regulation of megakaryocyte differentiation. Stem Cells 2001; 19: 397407.
  • 12
    Goldfarb AN. Transcriptional control of megakaryocyte development. Oncogene 2007; 26: 6795802.
  • 13
    Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J 1997; 16: 396573.
  • 14
    Hart A, Melet F, Grossfeld P, Chien K, Jones C, Tunnacliffe A, Favier R, Bernstein A. Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia. Immunity 2000; 13: 16777.
  • 15
    Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, Jackson CW, Hunt P, Saris CJ, Orkin SH. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell 1995; 81: 695704.
  • 16
    Tsang AP, Visvader JE, Turner CA, Fujiwara Y, Yu C, Weiss MJ, Crossley M, Orkin SH. FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation. Cell 1997; 90: 10919.
  • 17
    Wang X, Crispino JD, Letting DL, Nakazawa M, Poncz M, Blobel GA. Control of megakaryocyte-specific gene expression by GATA-1 and FOG-1: role of Ets transcription factors. EMBO J 2002; 21: 522534.
  • 18
    Takayama M, Fujita R, Suzuki M, Okuyama R, Aiba S, Motohashi H, Yamamoto M. Genetic analysis of hierarchical regulation for Gata1 and NF-E2 p45 gene expression in megakaryopoiesis. Mol Cell Biol 2010; 30: 266880.
  • 19
    Goncalves F, Lacout C, Feger F, Cohen-Solal K, Guichard J, Cramer E, Vainchenker W, Duménil D. Inhibition of erythroid differentiation and induction of megakaryocytic differentiation by thrombopoietin are regulated by two different mechanisms in TPO-dependent UT-7/c-mpl and TF-1/c-mpl cell lines. Leukemia 1998; 12: 135566.
  • 20
    Hong Y, Duménil D, Van Der Loo B, Goncalves F, Vainchenker W, Erusalimsky JD. Protein kinase C mediates the mitogenic action of thrombopoietin in c-Mpl-expressing UT-7 cells. Blood 1998; 91: 81322.
  • 21
    Ramsfjell V, Borge OJ, Cui L, Jacobsen SE. Thrombopoietin directly and potently stimulates multilineage growth and progenitor cell expansion from primitive (CD34+ CD38–) human bone marrow progenitor cells: distinct and key interactions with the ligands for c-kit and flt3, and inhibitory effects of TGF-beta and TNF-alpha. J Immunol 1997; 158: 516977.
  • 22
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 4028.
  • 23
    Deveaux S, Filipe A, Lemarchandel V, Ghysdael J, Romeo PH, Mignotte V. Analysis of the thrombopoietin receptor (MPL) promoter implicates GATA and Ets proteins in the coregulation of megakaryocyte-specific genes. Blood 1996; 87: 467885.
  • 24
    Elagib KE, Racke FK, Mogass M, Khetawat R, Delehanty LL, Goldfarb AN. RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood 2003; 101: 433341.
  • 25
    Visvader J, Adams JM. Megakaryocytic differentiation induced in 416B myeloid cells by GATA-2 and GATA-3 transgenes or 5-azacytidine is tightly coupled to GATA-1 expression. Blood 1993; 82: 1493501.
  • 26
    Barbeau B, Barat C, Bergeron D, Rassart E. The GATA-1 and Spi-1 transcriptional factors bind to a GATA/EBS dual element in the Fli-1 exon 1. Oncogene 1999; 18: 553545.
  • 27
    Cantor AB, Orkin SH. Transcriptional regulation of erythropoiesis: an affair involving multiple partners. Oncogene 2002; 21: 336876.
  • 28
    Shivdasani RA, Orkin SH. Erythropoiesis and globin gene expression in mice lacking the transcription factor NF-E2. Proc Natl Acad Sci USA 1995; 92: 86904.
  • 29
    Athanasiou M, Mavrothalassitis G, Sun-Hoffman L, Blair DG. FLI-1 is a suppressor of erythroid differentiation in human hematopoietic cells. Leukemia 2000; 14: 43945.
  • 30
    McCarty JM, Melone PD, Simanis JP, Kanamori D, Dessypris EN, Warshamana-Greene GS. A preliminary investigation into the action of anagrelide: thrombopoietin–c-Mpl receptor interactions. Exp Hematol 2006; 34: 8796.
  • 31
    Pallard C, Gouilleux F, Benit L, Cocault L, Souyri M, Levy D, Groner B, Gisselbrecht S, Dusanter-Fourt I. Thrombopoietin activates a STAT5-like factor in hematopoietic cells. EMBO J 1995; 14: 284756.
  • 32
    Bouscary D, Lecoq-Lafon C, Chretien S, Zompi S, Fichelson S, Muller O, Porteu F, Dusanter-Fourt I, Gisselbrecht S, Mayeux P, Lacombe C. Role of Gab proteins in phosphatidylinositol 3-kinase activation by thrombopoietin (Tpo). Oncogene 2001; 20: 2197204.
  • 33
    Garcia J, De Gunzburg J, Eychene A, Gisselbrecht S, Porteu F. Thrombopoietin-mediated sustained activation of extracellular signal-regulated kinase in UT7-Mpl cells requires both Ras-Raf-1- and Rap1-B-Raf-dependent pathways. Mol Cell Biol 2001; 21: 265970.
  • 34
    Millot GA, Vainchenker W, Duménil D, Svinarchuk F. Differential signalling of NH2-terminal flag-labelled thrombopoietin receptor activated by TPO or anti-FLAG antibodies. Cell Signal 2004; 16: 35563.
  • 35
    Redig AJ, Platanias LC. The protein kinase C (PKC) family of proteins in cytokine signaling in hematopoiesis. J Interferon Cytokine Res 2007; 27: 62336.
  • 36
    Doornbos RP, Theelen M, Van Der Hoeven PC, Van Blitterswijk WJ, Verkleij AJ, Van Bergen en Henegouwen P. Protein kinase Czeta is a negative regulator of protein kinase B activity. J Biol Chem 1999; 274: 858996.
  • 37
    Motley ED, Kabir SM, Gardner CD, Eguchi K, Frank GD, Kuroki T, Ohba M, Yamakawa T, Eguchi S. Lysophosphatidylcholine inhibits insulin-induced Akt activation through protein kinase C-alpha in vascular smooth muscle cells. Hypertension 2002; 39: 50812.
  • 38
    Skoda RC, Seldin DC, Chiang MK, Peichel CL, Vogt TF, Leder P. Murine c-mpl: a member of the hematopoietic growth factor receptor superfamily that transduces a proliferative signal. EMBO J 1993; 12: 264553.
  • 39
    Pang L, Xue HH, Szalai G, Wang X, Wang Y, Watson DK, Leonard WJ, Blobel GA, Poncz M. Maturation stage-specific regulation of megakaryopoiesis by pointed-domain Ets proteins. Blood 2006; 108: 2198206.
  • 40
    Huang Z, Dore LC, Li Z, Orkin SH, Feng G, Lin S, Crispino JD. GATA-2 reinforces megakaryocyte development in the absence of GATA-1. Mol Cell Biol 2009; 29: 516880.
  • 41
    Kitajima K, Tanaka M, Zheng J, Yen H, Sato A, Sugiyama D, Umehara H, Sakai E, Nakano T. Redirecting differentiation of hematopoietic progenitors by a transcription factor, GATA-2. Blood 2006; 107: 185763.
  • 42
    Klimchenko O, Mori M, Distefano A, Langlois T, Larbret F, Lecluse Y, Feraud O, Vainchenker W, Norol F, Debili N. A common bipotent progenitor generates the erythroid and megakaryocyte lineages in embryonic stem cell-derived primitive hematopoiesis. Blood 2009; 114: 150617.
  • 43
    Silverstein MN, Petitt RM, Solberg LA Jr, Fleming JS, Knight RC, Schacter LP. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med 1988; 318: 12924.
  • 44
    Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001; 97: 8636.
  • 45
    Mazzucconi MG, Redi R, Bernasconi S, Bizzoni L, Dragoni F, Latagliata R, Santoro C, Mandelli F. A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica 2004; 89: 130613.
  • 46
    Rinaldi CR, Martinelli V, Rinaldi P, Ciancia R, Del Vecchio L. GATA1 is overexpressed in patients with essential thrombocythemia and polycythemia vera but not in patients with primary myelofibrosis or chronic myelogenous leukemia. Leuk Lymphoma 2008; 49: 141619.